249 episodes

The Blood Podcast summarizes content recently published in Blood, the most cited peer-reviewed publication in the field of hematology.

Blood Podcast American Society of Hematology

    • Science

The Blood Podcast summarizes content recently published in Blood, the most cited peer-reviewed publication in the field of hematology.

    Review Series on the Influence of the Tumor Microenvironment on the Pathogenesis of B-Cell Lymphomas

    Review Series on the Influence of the Tumor Microenvironment on the Pathogenesis of B-Cell Lymphomas

    In this bonus episode of Blood Podcast, Associate Editor, Dr. Freda Stevenson is joined by Drs. Karin Tarte, Andrea Ratke, and Leandro Cerchietti to discuss the Review Series on the influence of the tumor microenvironment on the pathogenesis of B-cell lymphomas.
    Find the full review series in Blood Journal volume 143 issue 12. 

    • 32 min
    Free light chain mass spectrometry in diagnosis and monitoring of AL amyloidosis; T cells of AML patients in remission have distinct RNA signatures; and protective effect of ADAMTS13 in sickle cell mice depends on von Willebrand factor clearance

    Free light chain mass spectrometry in diagnosis and monitoring of AL amyloidosis; T cells of AML patients in remission have distinct RNA signatures; and protective effect of ADAMTS13 in sickle cell mice depends on von Willebrand factor clearance

    In this week's episode we’ll discuss the findings from a study assessing the utility of free light chain mass spectrometry in AL amyloidosis, learn more about distinct single-cell RNA-sequencing signatures of bone marrow T cells of AML patients in remission after an allogeneic stem cell transplant, and discuss why von Willebrand factor clearance is critical for the protective effect of ADAMTS13 in mice with sickle cell anemia.
    Articles featured in this episode: 
    Clearance of VWF by hepatic macrophages is critical for the protective effect of ADAMTS13 in sickle cell anemia mice Complete responses in AL amyloidosis are unequal: the impact of free light chain mass spectrometry in AL amyloidosisThe remission status of patients with AML post-alloSCT is associated with a distinct single-cell bone marrow T-cell signature 

    • 22 min
    Eculizumab in transplant-associated thrombotic microangiopathy; reclassifying malignant monocytosis; targeting tissue factor in antiphospholipid syndrome

    Eculizumab in transplant-associated thrombotic microangiopathy; reclassifying malignant monocytosis; targeting tissue factor in antiphospholipid syndrome

    In this week's episode we'll discuss eculizumab in stem cell transplant-associated thrombotic microangiopathy. Then, we'll learn about reclassifying malignant monocytosis, these newly classified cases have distinct mutational and transcriptional profiles. Finally, we'll hear about targeting the tissue factor coagulation initiation complex prevents antiphospholipid antibody development.
    Articles featured in this episode:
     A prospective multi-institutional study of eculizumab to treat high-risk stem cell transplantation–associated TMA Comparing malignant monocytosis across the updated WHO and ICC classifications of 2022 Treatment outcomes of complement protein C5 inhibition in 509 UK patients with paroxysmal nocturnal hemoglobinuria

    • 20 min
    Identification of rare relapse-initiating stem cells post-transplantation; interferon α impairs erythropoiesis in sickle cell disease; TNFα promotes clonal dominance of KIT D816V+ cells in mastocytosis

    Identification of rare relapse-initiating stem cells post-transplantation; interferon α impairs erythropoiesis in sickle cell disease; TNFα promotes clonal dominance of KIT D816V+ cells in mastocytosis

    In this week's episode we’ll learn more about rare relapse-initiating stem cells in patients with MDS or AML in complete remission post-transplantation, discuss the role of interferon α in erythropoiesis in sickle cell disease, and learn more about how TNFα promotes clonal dominance of KIT D816V+ cells in mastocytosis.

    • 22 min
    How PAR2 signaling drives thrombo-inflammation; pretransfusion hemoglobin levels linked to survival in beta-thalassemia; etoposide is better than its reputation in primary HLH

    How PAR2 signaling drives thrombo-inflammation; pretransfusion hemoglobin levels linked to survival in beta-thalassemia; etoposide is better than its reputation in primary HLH

    In this week's episode we'll discuss PAR2-biased signaling in thrombo-inflammation. Then, we'll learn about how hemoglobin levels are linked to survival in transfusion-dependent beta-thalassemia. Finally we'll hear about how etoposide is better than its reputation in primary HLH—hemophagocytic lymphohistiocytosis. Symptomatic patients treated with etoposide have substantially better outcomes as compared to the historical experience.

    • 17 min
    Brentuximab vedotin plus dacarbazine or nivolumab in classical Hodgkin lymphoma; loss of CD20 causes resistance to mosunetuzumab in r/r B-cell lymphomas; trogocytosis as a driver of RBC antigen loss

    Brentuximab vedotin plus dacarbazine or nivolumab in classical Hodgkin lymphoma; loss of CD20 causes resistance to mosunetuzumab in r/r B-cell lymphomas; trogocytosis as a driver of RBC antigen loss

    In this week's episode we’ll discuss the findings from a prospective trial of brentuximab vedotin with dacarbazine or nivolumab in older patients with classical Hodgkin lymphoma, learn more about CD20 antigen loss as a mechanism of resistance to mosunetuzumab in relapsed/refractory B-cell lymphomas, and discuss the role of trogocytosis in red blood cell antigen loss.

    • 23 min

Top Podcasts In Science

The Physio Matters Podcast
Jack Chew
Heal NPD
Mark Ettensohn, Psy.D.
ShoSalfa? | شسالفة؟
Imane
StarTalk Radio
Neil deGrasse Tyson
The Orthobullets Podcast
Orthobullets
Maloom | معلوم
Sowt | صوت

You Might Also Like

The Hematologist
The Hematologist
NEJM This Week
NEJM Group
Two Onc Docs
Sam and Karine
JAMA Editors' Summary
JAMA Network
Hematologic Oncology Update
Dr Neil Love
JAMA Clinical Reviews
JAMA Network